Rasha Aguzzi
About
Rasha Aguzzi is a scholar working on Neurology, Immunology and Genetics.
According to data from OpenAlex, Rasha Aguzzi has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 9 papers in Immunology and 6 papers in Genetics. Recurrent topics in Rasha Aguzzi's work include Myasthenia Gravis and Thymoma (9 papers), Complement system in diseases (8 papers) and Peripheral Neuropathies and Disorders (7 papers). Rasha Aguzzi is often cited by papers focused on Myasthenia Gravis and Thymoma (9 papers), Complement system in diseases (8 papers) and Peripheral Neuropathies and Disorders (7 papers). Rasha Aguzzi collaborates with scholars based in United States, France and Italy. Rasha Aguzzi's co-authors include Pierre Paré, Margaret K. Vandervoort, John WD McDonald, Irving H. Fox, Richard N. Fedorak, Albert Cohen, Brian G. Feagan, Steven B. Landau, A. Hillary Steinhart and Gordon R. Greenberg and has published in prestigious journals such as New England Journal of Medicine, Blood and Neurology.
In The Last Decade
Rasha Aguzzi
22 papers receiving 1.2k citations
Hit Papers
Peers
Rasha Aguzzi
Britta Höchsmann Germany
Alexander J. Cole Australia
Francesca Gaia Rossi Italy
DG Wright United States
Kerry Dobbs United States
Hirohito Yamazaki Japan
Víctor H. Jiménez‐Zepeda Canada
Mildred Wilson United States
Catharina Schuetz Germany
Gil Bornstein Israel
Citations per year, relative to Rasha Aguzzi Rasha Aguzzi (= 1×)
peers
Britta Höchsmann
Countries citing papers authored by Rasha Aguzzi
Since
Specialization
Citations
This map shows the geographic impact of Rasha Aguzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rasha Aguzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rasha Aguzzi more than expected).
Fields of papers citing papers by Rasha Aguzzi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rasha Aguzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rasha Aguzzi. The network helps show where Rasha Aguzzi may publish in the future.
Co-authorship network of co-authors of Rasha Aguzzi
This figure shows the co-authorship network connecting the top 25 collaborators of Rasha Aguzzi. A scholar is included among the top collaborators of Rasha Aguzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rasha Aguzzi. Rasha Aguzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vu, Tuan H., Renato Mantegazza, Djillali Annane, et al.. (2025). Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension. European Journal of Neurology. 32(4). e70158–e70158.
2.
Annane, Djillali, Andreas Meisel, Masahisa Katsuno, et al.. (2024). P.053 Concomitant corticosteroid use in ravulizumab-treated adults with anti-AChR antibody-positive gMG: results from the CHAMPION MG open-label extension. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51(s1). S30–S30.
3.
Vu, Tuan, Renato Mantegazza, Djillali Annane, et al.. (2024). 506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension. Neuromuscular Disorders. 43. 104441.639–104441.639.
4.
Vu, Tuan, Andreas Meisel, Renato Mantegazza, et al.. (2023). Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. Neurology and Therapy. 12(5). 1435–1438.
5.
Vu, Tuan, Stephan Ortiz, Masahisa Katsuno, et al.. (2023). Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Journal of Neurology. 270(6). 3129–3137.
6.
Meisel, Andreas, Djillali Annane, Tuan Vu, et al.. (2023). Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Journal of Neurology. 270(8). 3862–3875.
7.
Vu, Tuan, Andreas Meisel, Renato Mantegazza, et al.. (2022). Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P1-1.Virtual). Neurology. 98(18_supplement).
8.
Howard, James F., Tuan Vu, Renato Mantegazza, et al.. (2022). Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Open-label Extension (S25.005). Neurology. 98(18_supplement).
9.
Ishiyama, Ken, Shinji Nakao, Kensuke Usuki, et al.. (2020). Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. International Journal of Hematology. 112(4). 466–476.
10.
Latour, Régis Peffault de, Robert A. Brodsky, Stephan Ortiz, et al.. (2020). Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. British Journal of Haematology. 191(3). 476–485.
11.
Latour, Régis Peffault de, Robert A. Brodsky, Stephan Ortiz, et al.. (2018). Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. Blood. 132(Supplement 1). 626–626.
12.
Weitz, Ilene C., Alexander Kulagin, Shinji Nakao, et al.. (2018). A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics. Blood. 132(Supplement 1). 627–627.
13.
Lee, Jong Wook, Flore Sicre de Fontbrune, Lily Wong Lee Lee, et al.. (2018). Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 133(6). 530–539.
14.
Lee, Jong‐Wook, Eric Bachman, Rasha Aguzzi, et al.. (2016). Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study. Blood. 128(22). 2428–2428.
15.
Kamath, Ravi S., Elena Lukina, Nora Watman, et al.. (2014). Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiology. 43(10). 1353–1360.
16.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment. Blood. 120(21). 1038–1038.
17.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results. Molecular Genetics and Metabolism. 105(2). S52–S52.
18.
Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2011). Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years. Blood. 118(21). 1104–1104.
19.
Peterschmitt, Michel, Ravi S. Kamath, Elena Lukina, et al.. (2011). Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,. Blood. 118(21). 3216–3216.
20.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2005). Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin. New England Journal of Medicine. 352(24). 2499–2507.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Britta Höchsmann Breakdown of academic impact, for papers by Alexander J. Cole Breakdown of academic impact, for papers by Francesca Gaia Rossi Breakdown of academic impact, for papers by DG Wright Breakdown of academic impact, for papers by Kerry Dobbs Breakdown of academic impact, for papers by Hirohito Yamazaki Breakdown of academic impact, for papers by Víctor H. Jiménez‐Zepeda Breakdown of academic impact, for papers by Mildred Wilson Breakdown of academic impact, for papers by Catharina Schuetz Breakdown of academic impact, for papers by Gil Bornstein